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Room 9A27, Bethesda, MD 20892-1800, USASee Article, pages 111–117The dramatic growth of the pharmaceutical industry
over the past 50–60 years has resulted in the develop-
ment and marketing of an ever-increasing number of
drugs. In the United States, medical drugs, both over-
the-counter and those dispensed by prescription, are
widely advertised on television, in the popular press,
and on the worldwide web. The result is that the general
public, especially in western countries, are accustomed
to hearing about drugs and have come to expect their
availability for all ailments, regardless of their severities.
While most conventional drugs are designed to be ben-
eﬁcial, they can also cause undesired adverse eﬀects that
may range from trivial to death-dealing injury. Numer-
ous epidemiologic surveys indicate that adverse reac-
tions from conventional drugs account for between 3%
and over 8% of all hospital admissions [1–4], and are
responsible for a signiﬁcant number of deaths [1,5,6].
Adverse reactions can aﬀect all organ systems including
the liver, the focus of this editorial.
Herbals and dietary supplements also now play an
important role in the ‘‘therapeutic armamentarium.”
Herbals have been utilized by indigenous peoples and
certain cultures for centuries, but interest in their use
among western populations is a relatively recent phe-
nomenon, although their frequency of use is growing
exponentially and is beginning to parallel and even
exceed that of conventional medications. In early tele-
phone surveys conducted in the United States, the use0168-8278/$34.00 Published by Elsevier B.V. on behalf of the European Ass
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was reported to increase among respondents from 34%
in 1990 [7] to 42% in 1997 [8]. Evaluation of data from
the National Health and Nutrition Evaluation Survey
(NHANES) found that, between 1999 and 2000, dietary
supplements were used by 52% of the surveyed popula-
tion [9], and in another Health and Diet Survey con-
ducted in the United States, as many as 73% of
persons interviewed indicated they had taken dietary
supplements in the preceding 12 months, 4% reporting
associated adverse events [10]. Herbals use is particu-
larly frequent by people with chronic diseases, including
chronic liver disease, in the belief that they provide ben-
eﬁt both in treating their illnesses and in improving their
sense of well-being. [11–13] The global market for CAM
is said to exceed $60 billion and to have cost $17 billion
in the US alone in the year 2000 [8].
There are several reasons for the increasing attention
paid by the public to CAM. For some, there is waning
conﬁdence or disillusionment in conventional medical
practitioners who are perceived as frequently unavail-
able and often lacking in empathy; others consider it
important to take charge of their own lives; and for still
others, there are concerns about the often unpleasant
and sometimes serious adverse eﬀects of conventional
medicines, believing that since herbals are ‘‘natural”
and have been used for centuries, they must be safer.
This is, of course, an incorrect assumption since numer-
ous herbals, like conventional medicines, have been
identiﬁed to cause adverse reactions, including hepato-
toxicity [14–16].
Allopathic (conventional) physicians are generally
suspicious of herbal products, questioning both their
value and their safety. Reassuring proof of eﬃcacy is
lacking because few herbal products have been evaluatedociation for the Study of the Liver.
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the spreading focus on herbals by the public stems lar-
gely from word-of-mouth information, published indi-
vidual testimonials, and wide-spread advertising.
Regarding safety, the concern, certainly in the United
States, is that since herbal products are categorized as
dietary supplements, they cannot be labeled as a treat-
ment for disease. They are therefore exempt from requir-
ing approval for use by the Food and Drug
Administration, as is the regulation for conventional
drugs [18]. Similarly, in Europe, where herbals also are
regarded as food supplements, there had previously been
no safety regulations common to all countries. In 2004,
a European Directive was proposed by the European
Parliament and Council of Europe requiring authoriza-
tion by regulatory authorities in each European country
in regard to eﬃcacy and safety issues [19]. Safety issues
include the concern about the purity of herbals as well as
uncertainty about whether their content is accurately
displayed on the label. Although most users of herbals
believe they are safe, many herbals have been clearly
implicated as causes of hepatotoxicity, and indeed, sev-
eral products, such as kava kava and LipoKinetix, have
been restricted or removed from use in the US and Ger-
many because of their frequency and severity of injury
to the liver [20,21]. Particularly concerning are herbal
mixtures that contain multiple ingredients, not all of
which are identiﬁable. Therefore, if liver injury should
occur, it may be diﬃcult or impossible to identify which
component is responsible. An additional concern is that
some herbal products have been shown to contain
potentially toxic contaminants such as lead, mercury
or arsenic [22–24]. Indeed, many herbals and weight loss
products known to have caused liver injury are pur-
chased via the internet [25].
The relative contribution of herbal-related liver
injury to the overall frequency of all cases of hepato-
toxicity is not well established but probably varies by
geographic region. In an ongoing multicenter study in
the United States – the Drug-Induced Liver Injury
Network (DILIN) study supported by the National
Institute of Diabetes and Digestive and Kidney Dis-
eases – approximately 10% of the ﬁrst 300 cases of
identiﬁed drug-induced liver injury were attributed to
one or more herbal product [26]. In contrast, in a
study reported from Singapore, 52% of 29 cases of
drug-induced liver injury seen in the course of one
year were caused by traditional Chinese medicines
[27]. Determining the occurrence of drug-induced liver
injury is, however, challenging. Without a speciﬁc
diagnostic biomarker, drug-induced liver injury must
be considered whenever liver dysfunction is identiﬁed
for which there is no obvious etiology other than
the temporal receipt of a drug. The diagnosis of hep-
atotoxicity, however, requires that its possibility be
considered and that the aﬀected person is carefullyinterrogated about all drugs used; unfortunately, inter-
viewers not uncommonly neglect to inquire about the
use of herbals and therefore their contribution to the
problem of drug-induced liver injury may be underes-
timated. Also the diagnostic strategy most commonly
used to make a diagnosis of drug-induced liver injury
– the RUCAM causality assessment instrument [28] –
has potential drawbacks [29].
In this issue of the Journal of Hepatology, Stickel
and co-workers describe two cases of severe liver
injury that they attribute to Herbalife products
[30]. One patient had used Herbalife F1 Shake
Strawberry and Cappuccino, and the other had con-
sumed multiple diverse Herbalife products. The liver
disease in the ﬁrst patient manifested as cholestatic
and lobular/portal hepatitis with cirrhosis, and in the
other as biliary ﬁbrosis and ductopenia. Because of
the diﬃculty in determining the precise contents of
these products, the authors sought contaminants as a
potential basis for the liver injury, and after careful
study, identiﬁed the presence of Bacillus subtilis in
some of the products ingested by both patients, show-
ing also that cultures of the bacteria induced dose-
dependent leakage of LDH from HepaG2 cells which
they interpreted as the basis for the liver injury.
Another possible mechanism advanced was the possi-
bility of drug-induced autoimmune hepatitis because
of the identiﬁcation of a positive ANA of 1:1280 in
the one patient and 1:160 in the other. While autoim-
mune hepatitis as an adverse reaction to drugs has
been well described [31], it more commonly presents
as hepatocellular rather than as cholestatic liver dis-
ease. It is conceivable, as suggested by the authors,
that bacterial contamination was indeed responsible
for the liver disease, but Gram-positive bacteria are
extremely rare causes for liver injury, so that it is
unclear whether the identiﬁed bacterium truly
accounted for the identiﬁed liver disease despite the
evidence of enzyme leakage.
Still, there are at least three reports of liver injury
attributed to Herbalife products, one from Israel [32],
another from Switzerland [33], and a third from Spain
[34]. Together, these 4 reports describe 28 cases of liver
injury attributed to Herbalife. Two aﬀected patients
developed fulminant hepatitis requiring liver transplan-
tation. The manifestation of liver disease ran the gamut
from a hepatocellular, to a mixed, to a cholestatic pat-
tern. All the authors used reasonable strategies to impli-
cate the Herbalife products, but not all the cases
received the highest grades of causality scoring; some
were called probable rather than certain. However it
seems quite likely that liver injury does occur among
some people who receive these products, but the precise
mechanism or responsible agent in the herbal products is
uncertain, in part because the complete listing of the
ingredients of these products are not known and the
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needed information.
Undoubtedly, deﬁnitively establishing causality in the
face of existing liver disease can be diﬃcult. This has
prompted Herbalife personnel to strongly question
whether the described hepatotoxicity cases, some with
other liver diseases, can really be attributed to their
products [35]. This questioning is not uncommon by
manufacturers of drugs – conventional and alternative
– when instances of drug-induced liver injury involving
their products are reported. Until a speciﬁc biomarker
is identiﬁed, there will always be some uncertainty in
implicating a speciﬁc product as a potential hepatotoxin.
However, the causality likelihood is greatly increased
when there are multiple reports, particularly if from
well-regarded investigators.
Finally, both conventional drugs and herbals are
well-known to cause drug-induced liver injury. The
greater concern about alternative medications is that,
since they are not regulated in the same way as con-
ventional drugs, their entire contents, advertised and
otherwise, may not be known. Ideally, all medicinal
products consumed by the public, whether conven-
tional or alternative, should be subjected to the same
safety scrutiny. Until that occurs, manufacturers of
herbals should be completely transparent about their
products by openly reporting all ingredients contained
in the product as well as the dose of each of them.
Consumers, however, should be aware that herbals
are no safer than conventional medications.References
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